Search
LetibotulinumtoxinA
go.drugbank.com/drugs/DB16820Approved[L42335] It was approved for use in the treatment of glabellar lines in Canada in June 2022[L42330,L42335] and in the US in March 2024.[L50291,L50296] … [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.
Onasemnogene abeparvovec
go.drugbank.com/drugs/DB15528ApprovedInvestigational[A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms. … Onasemnogene abeparvovec is the first gene therapy that was approved for this indication in the USA.
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Acetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalIt is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections. … Acetohydroxamic Acid has no direct antimicrobial action and does not acidify urine directly.
Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylamineDaridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigationalConventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), serotonin, histamine, or melatonin receptors; however, undesirable side effects are frequently reported … [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023.
Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalIt has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. … Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction
Calaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalCalaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890]. … Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890].
Categories: Compounds used in a research, industrial, or household settingDidanosine
go.drugbank.com/drugs/DB00900ApprovedInvestigationalA dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. … This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseProducts: DE LIBERACION RETARDADA X 125 MG, DE LIBERACION RETARDADA X 400 MGVibrio cholerae CVD 103-HgR strain live antigen
go.drugbank.com/drugs/DB14443ApprovedInvestigationalprevention to become available in the U.S. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]
Pregabalin
go.drugbank.com/drugs/DB00230ApprovedInvestigational[L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161] … Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.
Products: Nb-pregabalin, PREGABALINA CÁPSULAS X 300 MG